CN115484955A - Aminopyridine derivatives for the treatment of disorders of MET gene abnormality - Google Patents
Aminopyridine derivatives for the treatment of disorders of MET gene abnormality Download PDFInfo
- Publication number
- CN115484955A CN115484955A CN202180030830.7A CN202180030830A CN115484955A CN 115484955 A CN115484955 A CN 115484955A CN 202180030830 A CN202180030830 A CN 202180030830A CN 115484955 A CN115484955 A CN 115484955A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- met gene
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150105382 MET gene Proteins 0.000 title claims abstract description 113
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 61
- 230000005861 gene abnormality Effects 0.000 title claims abstract description 23
- 150000003927 aminopyridines Chemical class 0.000 title abstract description 3
- 208000035475 disorder Diseases 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 136
- 150000003839 salts Chemical class 0.000 claims abstract description 103
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 83
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 83
- 201000010099 disease Diseases 0.000 claims abstract description 55
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 33
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 32
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 27
- 230000002159 abnormal effect Effects 0.000 claims description 24
- 230000004544 DNA amplification Effects 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 206010064571 Gene mutation Diseases 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 230000002018 overexpression Effects 0.000 claims description 11
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000002651 drug therapy Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000008707 rearrangement Effects 0.000 claims description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 235000013985 cinnamic acid Nutrition 0.000 claims description 3
- 229930016911 cinnamic acid Natural products 0.000 claims description 3
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- 229960002510 mandelic acid Drugs 0.000 claims description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940071870 hydroiodic acid Drugs 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 150000003930 2-aminopyridines Chemical class 0.000 abstract description 3
- BVGDAZBTIVRTGO-UONOGXRCSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2s)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine Chemical compound C1([C@@H](C)OC=2C(N)=NC=C(C=2)C2=CN=C(C=C2OC)N2[C@H](CNCC2)C)=C(Cl)C=CC(F)=C1Cl BVGDAZBTIVRTGO-UONOGXRCSA-N 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 20
- 230000003902 lesion Effects 0.000 description 18
- 230000035772 mutation Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 206010027476 Metastases Diseases 0.000 description 14
- 208000009956 adenocarcinoma Diseases 0.000 description 14
- 230000009401 metastasis Effects 0.000 description 14
- 238000007917 intracranial administration Methods 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- 230000001594 aberrant effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 150000001860 citric acid derivatives Chemical class 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 6
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 5
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 229960005061 crizotinib Drugs 0.000 description 5
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 5
- -1 difurofluorouracil Chemical compound 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000005015 mediastinal lymph node Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 210000004224 pleura Anatomy 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000002620 vena cava superior Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229950007440 icotinib Drugs 0.000 description 3
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- NSRVTWFLOSHWDX-UHFFFAOYSA-N Tremulin Natural products CC12CCCC(C)(C1CCC34CC(C(O)CC23)C(=C)C4=O)C(=O)O NSRVTWFLOSHWDX-UHFFFAOYSA-N 0.000 description 2
- IIJQICKYWPGJDT-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound N.N.[Pt+2].OC(=O)C1(C([O-])=O)CCC1.OC(=O)C1(C([O-])=O)CCC1 IIJQICKYWPGJDT-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 208000013210 hematogenous Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 2
- 208000022822 lung sarcomatoid carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- WBLWTVLKQDRNHL-LMRHVHIWSA-N 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2S)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.COc1cc(ncc1-c1cnc(N)c(O[C@H](C)c2c(Cl)ccc(F)c2Cl)c1)N1CCNC[C@@H]1C WBLWTVLKQDRNHL-LMRHVHIWSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 101500016898 Arabidopsis thaliana C-terminally encoded peptide 7 Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241001468684 Diplocardia Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241001495452 Podophyllum Species 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229950002777 miboplatin Drugs 0.000 description 1
- 190000032366 miboplatin Chemical compound 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- FIOKOSHFWPOUGX-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethyl]-2-(4-nitrophenoxy)acetamide Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(=O)COC1=CC=C([N+]([O-])=O)C=C1 FIOKOSHFWPOUGX-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present application relates to aminopyridine derivatives useful for treating diseases with MET gene abnormalities. In particular, the application relates to the use of substituted 2-aminopyridine derivatives for the treatment of non-small cell lung cancer with MET gene abnormality and gastric cancer with MET gene abnormality. The 2-aminopyridine derivative is, for example, compound I or a pharmaceutically acceptable salt thereof, having the chemical name 5- ((R) -1- (2, 6-dichloro-3-fluorophenyl) ethoxy) -4' -methoxy-6 ' - ((S) -2-methylpiperazin-1-yl) -3,3' -bipyridin-6-amine.
Description
Cross Reference to Related Applications
This application claims the benefit and priority of the chinese patent application No. 202010366117.7 filed on 30.04.2020 by the national intellectual property office of the people's republic of china, the entire contents of which are hereby incorporated by reference in their entirety.
The present application belongs to the field of medicine, and in particular, it relates to the use of substituted 2-aminopyridine derivatives in the treatment of diseases with MET gene abnormality.
The MET protooncogene is present in the long arm of human chromosome 7, the protein product is the c-MET tyrosine kinase receptor, and the MET gene is expressed both in embryonic and adult stages. The ligand of c-MET is hepatocyte-derived growth factor (HGF), and the binding of HGF and c-MET promotes proliferation, migration, differentiation and morphological changes of cells. The HGF/c-MET signaling pathway is subject to complex, high degree of regulation, playing an important role in cell proliferation, differentiation and motility. c-MET is combined with HGF to activate a plurality of downstream channels such as PI3K/Ak/mTOR, ras-MAPK and the like, so that the drug resistance phenomenon is caused; meanwhile, c-MET can be combined with HER3 to form a heterodimer so as to activate a downstream pathway.
The HGF/c-MET signal channel is abnormal by the following three mechanisms: 1. gene aspects include gene rearrangement, activating mutations, and gene amplification; 2. overexpression of c-MET protein due to transcriptional upregulation; 3. sustained activation of c-MET proteins is enabled by ligand-dependent autocrine or paracrine mechanisms.
The MET gene amplification comprises two different modes of overall amplification and regional amplification. The overall amplification is caused by the increase of the number of chromosome 7, is often accompanied by the amplification of other genes, and the MET gene amplification in the form is not considered to cause tumorigenesis and drug resistance at present; the mode of regional amplification, i.e. independent copy number of the MET gene, is increased.
In addition to MET gene amplification, exon 14 skipping mutations are currently considered to be important independent driver mutations in NSCLC (non-small cell lung cancer). The current clinical pathological characteristics research shows that the MET gene 14 exon skipping mutation mostly occurs in NSCLC, and lung sarcomatoid carcinoma and adenocarcinoma are the most common. The MET gene exon 14 skipping mutant population is older and has more smoking history. Therefore, the development of targeted drugs for treating MET gene abnormal diseases is necessary. And the analysis and research on the drug resistance mechanism of the drug have important guiding significance for the subsequent development of the drug and the subsequent medication of patients.
Summary of The Invention
In a first aspect, the application provides the use of compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease with abnormal MET gene,
in a second aspect, the application provides a method of treating a disease with MET gene abnormality, comprising administering to a patient in need thereof a therapeutically effective amount of compound I or a pharmaceutically acceptable salt thereof.
In a third aspect, the present application provides a pharmaceutical composition for treating a disease with abnormal MET gene, comprising compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
In a fourth aspect, the present application provides a kit comprising (a) at least one unit dose of a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating a disease in which the MET gene is aberrant.
In a fifth aspect, the present application provides compound I or a pharmaceutically acceptable salt thereof for use in the treatment of a disease in which the MET gene is aberrant.
In a sixth aspect, the present application provides the use of compound I, or a pharmaceutically acceptable salt thereof, in the treatment of a disease in which the MET gene is aberrant.
Detailed Description
In a first aspect, the application provides the use of compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease with abnormal MET gene,
MET gene abnormalities described herein include, but are not limited to, MET gene amplification, MET gene rearrangement, MET gene mutation, and/or c-MET overexpression. Wherein the MET gene amplification includes but is not limited to primary MET gene amplification and acquired drug resistant MET gene amplification. The MET gene mutation includes, but is not limited to, exon 14 mutation, such as exon 14 skipping mutation.
In some embodiments of the present application, there is provided the use of compound I or a pharmaceutically acceptable salt thereof for treating a disease of MET gene amplification. In some embodiments, uses for treating diseases of MET gene rearrangement are provided. In some embodiments, uses for treating diseases in which MET gene is mutated are provided. In some embodiments, uses for treating diseases in which c-MET is overexpressed are provided. In some embodiments, there is provided a method for treating a cancer having a biological activity selected from the group consisting of: use of a disease in which two or more MET genes are abnormal in MET gene amplification, MET gene rearrangement, MET gene mutation, and c-MET overexpression. In some embodiments of the present application, the above-described treatment is achieved by administering a therapeutically effective amount of said compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof.
In some embodiments of the present application, there is provided use for treating a disease in which a primary MET gene is amplified. In some embodiments, uses are provided for treating diseases of acquired drug resistant MET gene amplification. In some embodiments, uses for treating diseases in which the MET gene is globally amplified are provided. In some embodiments, there is provided a use for treating a disease in which a MET gene region is amplified. In some embodiments, MET gene amplification refers to an average gene copy number of ≧ 5 and/or a MET/CEP-7 copy number ratio (ratio of MET copy number to chromosome 7 centromere number) of ≧ 2. In some embodiments of the present application, the above treatment is achieved by administering said compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof.
In some embodiments of the present application, there is provided a use for treating a disease in which MET gene exon 14 is mutated. In some embodiments, there is provided a use for treating a disease with exon 14 skipping mutation of the MET gene. In some embodiments of the present application, the above treatment is achieved by administering said compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof.
In some embodiments of the present application, the disorder in which MET gene is aberrant is a disorder in which at least one chemotherapeutic drug and/or targeted drug treatment fails. In some embodiments, the disorder in which MET gene is aberrant is a disorder in which MET gene has previously received at least one chemotherapeutic and/or targeted drug.
In some embodiments, the disease in which MET gene is abnormal is selected from non-small cell lung cancer in which MET gene is abnormal or gastric cancer in which MET gene is abnormal.
In some embodiments of the present application, there is provided a use for treating non-small cell lung cancer with MET gene abnormality. In some embodiments, the non-small cell lung cancer is non-squamous carcinoma. In some specific embodiments, the non-small cell lung cancer is adenocarcinoma. In some specific embodiments, the non-small cell lung cancer is invasive adenocarcinoma. In some embodiments, the non-small cell lung cancer is a pulmonary sarcomatoid carcinoma. In some embodiments, the non-small cell lung cancer is squamous carcinoma. In some embodiments of the present application, the above treatment is achieved by administering said compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof. In some embodiments, the non-small cell lung cancer is one that has failed treatment with at least one chemotherapeutic and/or targeted drug. In some embodiments, the non-small cell lung cancer is one that has failed treatment with at least one or two chemotherapeutic agents. In some embodiments, the non-small cell lung cancer is a non-small cell lung cancer that has not previously been treated systemically.
In some embodiments of the present application, the present application provides a use of compound I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of non-small cell lung cancer with chemotherapeutic drugs and/or MET gene abnormalities that target drug resistance. In some embodiments, there is provided a use of compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating non-small cell lung cancer that has failed chemotherapy and/or targeted drug therapy.
In some embodiments of the present application, there is provided the use of compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the treatment of gastric cancer. In some embodiments, the gastric cancer is gastric cancer with MET gene abnormality. In some embodiments, the above treatment is achieved by administering said compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof. In some embodiments, the present application provides the use of compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of gastric cancer with chemotherapeutic drugs and/or MET gene abnormalities that target drug resistance. In some embodiments, there is provided the use of compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of gastric cancer that has failed chemotherapy and/or targeted drug therapy for MET gene abnormalities.
In a second aspect, the present application provides a method of treating a disease with abnormal MET gene, comprising administering to a subject in need thereof a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof,
in some embodiments of the present application, the MET gene abnormality is selected from the group consisting of: one or more of MET gene amplification, MET gene rearrangement, MET gene mutation, and c-MET overexpression. In some embodiments, the MET gene mutation is a MET gene exon 14 skipping mutation. In some embodiments, MET gene amplification refers to an average gene copy number of ≧ 5 and/or a MET/CEP-7 copy number ratio of ≧ 2.
In certain embodiments of the present application, the subject has non-small cell lung cancer. The non-small cell lung cancer includes but is not limited to adenocarcinoma, squamous cell carcinoma, large cell carcinoma or non-small cell lung cancer of undefined type; in some specific embodiments, the non-small cell lung cancer is non-squamous carcinoma; in some specific embodiments, the non-small cell lung cancer is adenocarcinoma; in some specific embodiments, the non-small cell lung cancer is invasive adenocarcinoma; in some specific embodiments, the non-small cell lung cancer is a sarcomatoid lung cancer; in some embodiments, the non-small cell lung cancer is squamous carcinoma.
In certain embodiments of the present application, the subject has locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic non-small cell lung cancer; wherein metastatic non-small cell lung cancer includes but is not limited to focal single metastasis, disseminated metastasis and diffuse metastasis; the metastatic lesions include, but are not limited to, lymph nodes, pleura, bone, brain, pericardium, adrenal gland, and liver. In some embodiments, the non-small cell lung cancer is brain metastatic non-small cell lung cancer. In some embodiments, the subject has relapsed non-small cell lung cancer including, but not limited to, intrabronchial blocked non-small cell lung cancer, resectable relapsed non-small cell lung cancer, mediastinal lymph node relapsed non-small cell lung cancer, superior Vena Cava (SVC) blocked non-small cell lung cancer, severely hemoptysed non-small cell lung cancer. In some embodiments, the subject is a non-small cell lung cancer patient who has previously failed at least one chemotherapeutic and/or targeted drug therapy. In some embodiments, the subject is a non-small cell lung cancer patient that has progressed or relapsed after prior treatment with at least one chemotherapeutic and/or targeted drug. In some embodiments, the subject is a non-small cell lung cancer patient that has not previously received systemic treatment.
In some embodiments of the present application, the non-small cell lung cancer is MET gene mutated non-small cell lung cancer; in some embodiments, the genetic mutation is an exon 14 skipping mutation. In some embodiments, the non-small cell lung cancer is MET gene-amplified non-small cell lung cancer; in some embodiments, the MET gene amplification means an average gene copy number of 5 or more and/or a MET/CEP-7 copy number ratio of 2 or more. In some embodiments, the non-small cell lung cancer is c-MET overexpressing non-small cell lung cancer.
In certain embodiments of the present application, the subject has locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic gastric cancer; wherein metastatic gastric cancer includes, but is not limited to, focal hematogenous metastasis, peritoneal colonization metastasis, and lymphatic metastasis; the metastatic lesions include, but are not limited to, lung, lymph node, pleura, bone, brain, pericardium, adrenal gland, liver, and pancreas. In some embodiments, the subject has recurrent gastric cancer. In some embodiments, the subject is a gastric cancer patient who has previously failed at least one chemotherapeutic and/or targeted drug therapy. In some embodiments, the subject is a patient with gastric cancer that has progressed or relapsed after prior treatment with at least one chemotherapeutic and/or targeted drug. In some embodiments, the subject is a patient with gastric cancer who has not previously received systemic treatment. In some embodiments of the present application, the gastric cancer is gastric cancer with a MET gene mutation; in some embodiments, the genetic mutation is an exon 14 skipping mutation. In some embodiments, the gastric cancer is a MET gene-amplified gastric cancer; in some embodiments, the MET gene amplification means that the average gene copy number is 5 or more and/or the MET/CEP-7 copy number ratio is 2 or more. In some embodiments, the gastric cancer is gastric cancer with c-MET protein overexpression.
The method of administration can be determined comprehensively on the basis of the activity, toxicity of the drug, tolerance of the patient, and the like. Preferably, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered as a daily continuous dose. The daily continuous administration may be about the same time as the morning and evening of each day. In some embodiments, compound I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is administered for one treatment cycle every 14 to 42 days; preferably, 21 days is one treatment cycle; preferably, 35 days is one treatment cycle; more preferably, 28 days is one treatment cycle; in some embodiments, compound I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is administered once or more times per day. Preferably, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered twice daily during the dosing period.
In some embodiments of the present application, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered on a daily basis, one dosing cycle every 28 days, with compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof being administered twice daily within the dosing cycle. In some embodiments, compound I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is administered at about the same time each day, 28 days being one dosing cycle, and compound I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is administered twice daily within the dosing cycle.
In certain specific embodiments of the present application, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered orally at a dose of 800mg per day, in two doses, for a cycle of 28 days.
In certain specific embodiments of the present application, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered orally at a dose of 1000mg per day, in two doses, for a cycle of 28 days.
In certain specific embodiments of the present application, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered orally at a dose of 1200mg per day, in two administrations over a 28 day cycle.
In certain specific embodiments of the present application, compound I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered orally at a dose of 1600mg per day, in two doses, over a 28 day cycle.
In some embodiments of the present application, the radiation therapy may be administered simultaneously or sequentially with a therapeutically effective amount of compound I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, to a patient in need thereof.
In a third aspect, the present application provides a pharmaceutical composition for treating a disease with abnormal MET gene, comprising compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
In some embodiments, the present application provides a pharmaceutical composition for treating MET gene-amplified non-small cell lung cancer, comprising compound I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; in some embodiments, the present application also provides a pharmaceutical composition for treating MET gene mutated non-small cell lung cancer, comprising compound I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; in some embodiments, the present application also provides a pharmaceutical composition for treating c-MET overexpressed non-small cell lung cancer, comprising compound I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. In some embodiments, the non-small cell lung cancer is locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic and/or relapsed non-small cell lung cancer. In some embodiments, the non-small cell lung cancer is a non-small cell lung cancer that has progressed or relapsed after prior treatment with at least one chemotherapeutic and/or targeted drug. In some embodiments, the non-small cell lung cancer is a non-small cell lung cancer that has not previously been treated systemically. In some embodiments, the non-small cell lung cancer is non-squamous; in some specific embodiments, the non-small cell lung cancer is adenocarcinoma. In some specific embodiments, the non-small cell lung cancer is invasive adenocarcinoma. In some specific embodiments, the non-small cell lung cancer is a sarcomatoid lung cancer. In some embodiments, the non-small cell lung cancer is squamous carcinoma.
In some embodiments, the present application provides a pharmaceutical composition for treating MET gene-amplified gastric cancer, comprising compound I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; in some embodiments, the present application provides a pharmaceutical composition for treating gastric cancer with MET gene mutation, comprising compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; in some embodiments, the present application provides a pharmaceutical composition for treating gastric cancer in which c-MET protein is overexpressed, comprising compound I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
In some embodiments of the present application, the pharmaceutical composition includes, but is not limited to, pharmaceutical compositions suitable for oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalation, vaginal, intraocular, topical, subcutaneous, intralipid, intraarticular, intraperitoneal, and intrathecal administration. In some embodiments, the pharmaceutical composition is a formulation suitable for oral administration, including tablets, capsules, powders, granules, pills, pastes, powders, and the like, preferably tablets and capsules.
In some embodiments of the present application, the pharmaceutical composition comprises 50 mg to 2000 mg of compound I or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg to 1600mg of compound I or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg to 1200mg of compound I or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg to 1000mg of compound I or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg to 800mg of compound I or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg-600 mg, 100 mg-150 mg, 100 mg-125 mg of compound I, or a pharmaceutically acceptable salt thereof; in some embodiments, the pharmaceutical composition comprises 100 mg, 125mg, 150 mg, 200mg, 250 mg, 300 mg, 350 mg, 375 mg, 400 mg, 450 mg, 500 mg, 600mg, 675 mg, 700 mg, 800mg, 900 mg, 1000mg, 1100 mg, 1200mg of compound I or a pharmaceutically acceptable salt thereof.
In some embodiments of the present application, there is provided a pharmaceutical composition formulated in unit dosage form for the treatment of a disease in which MET gene is aberrant; the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition in unit dosage form contains 50 mg to 1200mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition in unit dosage form contains 300 mg to 600mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition in unit dosage form contains 400 mg to 500 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition in unit dosage form contains 600mg to 1200mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition in unit dosage form contains 75 mg to 300 mg of compound I or a pharmaceutically acceptable salt thereof, preferably 100 mg to 200mg of compound I or a pharmaceutically acceptable salt thereof, more preferably 125mg to 175 mg of compound I or a pharmaceutically acceptable salt thereof. In some particular embodiments, the pharmaceutical composition in unit dosage form contains 50 mg, 100 mg, 125mg, 150 mg, 175 mg, 200mg of compound I or a pharmaceutically acceptable salt thereof. For example, with respect to tablets or capsules, a "pharmaceutical composition in unit dose form" means each tablet or each capsule.
In a fourth aspect, the present application provides a kit comprising (a) at least one unit dose of a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating a disease in which the MET gene is aberrant.
The present application also provides a kit comprising (a) at least one unit dose of an orally suitable formulation comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating a disease in which MET gene is aberrant. In some particular embodiments, a kit is provided comprising (a) at least one unit dose of a tablet or capsule comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating a disease with MET gene abnormality. In some particular embodiments, a kit is provided comprising (a) at least one unit dose of a tablet or capsule comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating non-small cell lung cancer with MET gene abnormality. In some particular embodiments, a kit is provided comprising (a) at least one unit dose of a tablet or capsule comprising compound I or a pharmaceutically acceptable salt thereof and (b) instructions for treating gastric cancer with MET gene abnormality. In some embodiments, the MET gene abnormality comprises one or more of MET gene amplification, MET gene rearrangement, MET gene mutation, c-MET overexpression. By "unit dose" is meant a pharmaceutical composition packaged in a single package for ease of administration, e.g., each tablet or capsule.
Compound I or a pharmaceutically acceptable salt thereof
Compound I of the present application has the chemical name 5- ((R) -1- (2, 6-dichloro-3-fluorophenyl) ethoxy) -4' -methoxy-6 ' - ((S) -2-methylpiperazin-1-yl) -3,3' -bipyridin-6-amine, which has the following structural formula:
compound I can be administered in its free base form, as well as in the form of its salts, hydrates, and prodrugs, which convert in vivo to the free base form of compound I. For example, pharmaceutically acceptable salts of compound I are within the scope of the present application, which salts can be produced from various organic and inorganic acids according to methods well known in the art.
In some embodiments herein, a pharmaceutically acceptable salt of compound I herein refers to a salt of compound I with a pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid is selected from the group consisting of sulfuric acid, carbonic acid, nitric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, metaphosphoric acid, trifluoroacetic acid, lactic acid, mandelic acid, glycolic acid, p-toluenesulfonic acid, o-toluenesulfonic acid, citric acid, methanesulfonic acid, formic acid, acetic acid, benzoic acid, phenylacetic acid, malonic acid, cinnamic acid, malic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, acrylic acid, crotonic acid, oleic acid, and linoleic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of sulfuric acid, hydrochloric acid, phosphoric acid, p-toluenesulfonic acid, citric acid, methanesulfonic acid, malic acid, maleic acid, tartaric acid, and fumaric acid. In some embodiments, the molar ratio of compound I to pharmaceutically acceptable acid in the salt is 1. In some embodiments, the pharmaceutically acceptable salt of compound I is the citrate salt of compound I. In some embodiments, the pharmaceutically acceptable acid is citric acid, and the molar ratio of compound I to citric acid is 1.
In some embodiments of the present application, compound I is administered as the citrate salt of compound I. In some embodiments, compound I is administered as the mono-citrate salt of compound I. In some embodiments, compound I is administered as the citrate salt of compound I. In some embodiments, the compound I is administered as a crystalline form of the citrate salt of compound I. In some embodiments, the compound I is administered as an amorphous form of the citrate salt.
Compound I or a pharmaceutically acceptable salt thereof may be administered by a variety of routes including, but not limited to, a route selected from: oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalation, vaginal, intraocular, topical administration, subcutaneous, intraadipogenic, intraarticular, intraperitoneal, and intrathecal. In some particular embodiments, administration is by oral administration.
The amount of compound I or a pharmaceutically acceptable salt thereof administered may be determined according to the severity of the disease, the response to the disease, any treatment-related toxicity, the age and health of the patient. In some embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is from 100 mg to 2000 mg. In some embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is from 150 mg to 1950 mg. In some embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is from 200mg to 1900 mg. In some embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is from 300 mg to 1800 mg. In some embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 450 mg to 1750 mg. In some embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 500 mg to 1650 mg. In some embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 750 mg to 1500 mg. In some embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 900 mg to 1350 mg. In some embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is 1050 mg to 1250 mg. In some particular embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 200 mg. In some particular embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is 400 mg. In some particular embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 600 mg. In some particular embodiments, the daily dose of compound I or a pharmaceutically acceptable salt thereof administered is 800 mg. In some particular embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is 1000 mg. In some particular embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is 1200 mg. In some particular embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt thereof, administered is 1600 mg.
Compound I or a pharmaceutically acceptable salt thereof may be administered one or more times per day. In some embodiments, compound I or a pharmaceutically acceptable salt thereof is administered once daily. In some embodiments, compound I or a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, compound I or a pharmaceutically acceptable salt thereof is administered twice daily in the form of an oral solid formulation.
Non-small cell lung cancer
In the present application, the non-small cell lung cancer is classified according to histology, and includes, but is not limited to, adenocarcinoma, squamous cell carcinoma, large cell carcinoma or non-small cell lung cancer with undefined type; according to clinical stage, including but not limited to locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic non-small cell lung cancer. Metastatic non-small cell lung cancer including but not limited to focal single metastasis, disseminated metastasis and diffuse metastasis; the metastatic lesions include, but are not limited to, lymph nodes, pleura, bone, brain, pericardium, adrenal gland, and liver. In some embodiments, the non-small cell lung cancer is brain metastatic non-small cell lung cancer. In some embodiments, the non-small cell lung cancer is recurrent non-small cell lung cancer, including, but not limited to, intrabronchial blocked non-small cell lung cancer, resectable recurrent non-small cell lung cancer, mediastinal lymph node recurrent non-small cell lung cancer, superior Vena Cava (SVC) blocked non-small cell lung cancer, severe hemoptytic non-small cell lung cancer.
Stomach cancer
In the present application, the gastric cancer, based on histological classification, includes, but is not limited to, adenocarcinoma, adenosquamous carcinoma, squamous carcinoma and carcinoid, wherein gastric adenocarcinoma includes, but is not limited to, papillary carcinoma, tubular adenocarcinoma, poorly differentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma, based on tissue structure. Gastric cancer includes, but is not limited to, highly differentiated gastric cancer, moderately differentiated gastric cancer and poorly differentiated gastric cancer according to the degree of cell differentiation. Gastric cancers include, but are not limited to, carcinoma of the fundus cardia, corpus gastris, and antrum gastris, depending on the classification of the site of incidence. Depending on the clinical stage, including but not limited to locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic gastric cancer. Metastatic gastric cancer includes, but is not limited to, focal hematogenous metastasis, peritoneal graft metastasis, and lymphatic metastasis; the metastatic lesions include, but are not limited to, lung, lymph node, pleura, bone, brain, pericardium, adrenal gland, liver, and pancreas.
Chemotherapy medicine
In the present application, the chemotherapeutic drug includes, but is not limited to, one or more of alkylating agents, podophyllum, camptothecin, taxus, antimetabolites, and antibiotic antineoplastic drugs. Examples that may be cited include, but are not limited to, platinum drugs (e.g., oxaliplatin, cisplatin, carboplatin, miboplatin, nedaplatin, dicycloplatin (dicycloplatin)), fluoropyrimidine derivatives (e.g., gemcitabine, capecitabine, fluorouracil, difurofluorouracil, doxifluridine, tegafur, carmofur, trifluridine), taxanes (e.g., paclitaxel, albumin-bound paclitaxel, paclitaxel liposomes, and docetaxel), camptothecins (e.g., camptothecin, hydroxycamptothecin, irinotecan, topotecan), vinblastines (vinorelbine, vincristine, vindesine, vinfuvinflunine (vinflunine)), pemetrexed, etoposide, irinotecan, mitomycin, ifosfamide, azacitidine, amrubicin, methotrexate, benzene, epirubicin, doxorubicin, temozolomide, LCL-161, KML-001, pacitabine, saproline (saprolin), tresultrin (octreotoxin), treulin (e), tremulin hydrochloride, tremulin, and one or two or three of them.
Targeted drugs
In the present application, the targeted drug includes, but is not limited to, tyrosine kinase inhibitors including, but not limited to, ALK inhibitors, EGFR inhibitors, VEGFR inhibitors, FGFR inhibitors, PDGFR inhibitors; in some embodiments, the targeted drugs include, but are not limited to, small molecule targeted drugs and antibodies; examples that may be cited include, but are not limited to, icotinib, aletinib (aletinib), crizotinib (Crizotinib), ceritinib (Ceritinib), bugatitinib (Brigatinib), cabozantinib (Cabozantinib), reritinib (SAF-189 s), enzatinib (X-396), loratinib (loretinib), and bevacizumab. In some typical embodiments, the targeted drug is erlotinib, crizotinib, enzatinib, loratinib, reritinib, and bevacizumab. In some more typical embodiments, the targeted drug is icotinib, bevacizumab or crizotinib. In some more typical embodiments, the targeted drug is crizotinib.
Herein, unless otherwise indicated, the dosages and ranges provided herein are based on the molecular weight of compound I in its free base form.
Unless otherwise indicated, the following terms used in the specification and claims shall have the following meanings for the purposes of this application.
"patient," "subject," or "subject" are used interchangeably and refer to a mammal, preferably a human.
By "pharmaceutically acceptable" is meant that it is used to prepare pharmaceutical compositions that are generally safe, non-toxic, and neither biologically nor otherwise undesirable, and include that they are acceptable for human pharmaceutical use.
"pharmaceutically acceptable salts" include, but are not limited to, acid addition salts formed with inorganic acids such as sulfuric, carbonic, nitric, hydrochloric, hydrobromic, hydroiodic, phosphoric, metaphosphoric, and the like; or with organic acids such as trifluoroacetic acid, lactic acid, mandelic acid, glycolic acid, p-toluenesulfonic acid, o-toluenesulfonic acid, citric acid, methanesulfonic acid, formic acid, acetic acid, benzoic acid, phenylacetic acid, malonic acid, cinnamic acid, malic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, acrylic acid, crotonic acid, oleic acid, linoleic acid and the like.
By "therapeutically effective amount" is meant an amount of a compound that, when administered to a subject, e.g., a human, for the treatment of a disease, is sufficient to effect treatment for the disease.
By "treatment" is meant any administration of a therapeutically effective amount of a compound and includes:
(1) Inhibiting the disease (i.e., arresting the further development of the pathology and/or symptomatology) in a human experiencing or exhibiting the pathology or symptomatology of the disease, or
(2) Ameliorating the disease (i.e., reversing the pathology and/or symptomatology) in a human experiencing or exhibiting the pathology or symptomatology of the disease.
"CR" means complete remission, "PR" means partial remission, "PD" means disease progression, "SD" means stable disease, "ORR" means objective remission rate, including CR + PR, "DCR" means disease control rate, including CR + PR + SD; these terms have meanings well known in the art, for example, as described in reference to the therapeutic efficacy assessment criteria for solid tumors (RECIST), version 1.1.
"treatment failure" includes intolerance of toxic side effects, disease progression during treatment, or relapse after treatment is complete; wherein intolerance includes, but is not limited to, hematologic toxicity up to grade IV (platelet lowering grade III and above), and non-hematologic toxicity up to grade III or above.
"c-MET overexpression" and "c-MET overexpression" are synonymous and used interchangeably.
"PFS (progression free survival) refers to the time from first drug enrollment to disease progression or death (on first-present basis).
"OS (overall survival)" means the time from first dose to full-blown death. Subjects who survived the last visit had OS scored as data loss at the time of the last visit. Subjects who were missed their OS counted as data loss by the time of last confirmed survival before the missed visit.
By "DOR (duration of disease remission)" is meant the time from the first recording of objective tumor remission (CR or PR) to the first recording of objective tumor progression or death for any reason, whichever occurs first.
"CNS-PFS (intracranial progression-free survival)" refers to the time from the start of enrollment to the first demonstration of intracranial progression in a baseline brain transfer subject.
"CNS-DCR (intracranial disease control rate)" means the proportion of subjects with complete remission, partial remission, and stable intracranial disease compared to subjects with target focal brain metastases at baseline.
"CNS-ORR (intracranial objective remission rate)" refers to the proportion of subjects with target focal brain metastases at baseline with complete intracranial remission, partial intracranial remission.
"CNS-TTP (to time of progression of intracranial disease)" means the time from the start of enrollment to the first appearance of progression of intracranial disease, including subjects with and without brain metastasis at baseline.
The present application is further illustrated below with reference to specific examples. It should be understood that these examples are only for illustrating the present application and are not intended to limit the scope of the present application.
Example 1- ((R) -1- (2, 6-dichloro-3-fluorophenyl) ethoxy) -4' -methoxy-6 ' - ((S) -2-methylpiperazin-1-yl) -3,3' -bipyridin-6-amine (Compound I) citrate (Compound I citrate)
The title compound can be prepared by reference to WO2016015676 "preparation of salt of pharmaceutically acceptable acid of compound of formula I".
Example 2 capsules containing 5- ((R) -1- (2, 6-dichloro-3-fluorophenyl) ethoxy) -4' -methoxy-6 ' - ((S) -2-methylpiperazin-1-yl) -3,3' -bipyridin-6-amine citrate (citrate salt of Compound I)
Uniformly mixing citrate of the compound I with microcrystalline cellulose, croscarmellose sodium and silicon dioxide; magnesium stearate is then added to the above mixture, mixed, dry granulated, and filled into capsules.
Capsules containing other amounts of compound I citrate can be prepared with reference to the same proportions and formulations described above.
Example 3
A certain number of cells (SNU-5) in logarithmic growth phase were inoculated into 96-well culture plates, and cultured for 72 hours with different concentrations of drugs. After the drug action is finished, MTT working solution is added into each hole, after 4 hours, the triple solution is dissolved, the temperature is kept overnight at 37 ℃, the OD value is measured by adopting an enzyme-labeling instrument at the wavelength of 570nm and 690nm the next day, and the OD is used 570 -OD 690 As the final OD value. The cell growth inhibition rate was calculated by the following formula:
inhibition rate = (OD value) Control well OD value Medicine feeding hole ) the/OD values are plotted against wells × 100%
Calculating half inhibitory concentration IC according to each concentration inhibition rate 50 The value is obtained.
TABLE 1 SNU-5 gastric cancer cell proliferation inhibition results of C-MET high expression by citrate of Compound I
Inhibition rate | Citrate salt of Compound I |
IC 50 (nM) | 179.3±2.5 |
Example 4
Inoculating 100ul Hs746T cells into a 96-well plate, incubating for 24h, taking 100uM citrate of the compound I, diluting by 4 times, feeding for 72h at 9 concentrations, adding CCK-8 reagent, incubating for 1-6h, measuring absorbance at 450nm, and calculating IC 50 The value is obtained.
TABLE 2 inhibition of Met-14 jump mutant Hs746T gastric cancer cell proliferation by citrate of Compound I
Inhibition rate | Citrate salt of Compound I |
IC 50 (nM) | 0.24 |
Example 5
In subjects who were histologically or cytologically confirmed to be non-small cell lung cancer (NSCLC) and who were stage IIIB-IV (judged according to the international association for the study of lung cancer and the american joint committee for cancer classification, 8 th edition), and who were assessed to be abnormal in MET gene status, one treatment cycle every 28 days, citrate capsules of compound I prepared in example 2 were administered with an initial daily dose of 1200mg (administered twice a day in the morning and evening, 600mg each), a regimen of continuous daily administration, either fasting at approximately the same time in the morning and evening or with meals, patients who received at least 1 treatment cycle were evaluated for efficacy, and clinical studies of safety and efficacy were conducted with Objective Remission Rate (ORR) as the primary efficacy endpoint, and intracranial disease control rate (CNS), total survival (total survival), DOR (duration of disease remission), CNS-PFS (non-progression), CNS-DCR (intracranial disease control rate), CNS-to-brain (TTP), and CNS-to-brain disease progression (TTP) as the secondary efficacy endpoints. The subjects are over 18 years old, unlimited in nature, have an ECOG score of 0-1, and are expected to have a survival time of greater than 12 weeks; according to RECIST v.1.1 standard, there is at least one measurable target lesion (brain lesion is not the only lesion).
The dosage administered can be adjusted as follows, if desired:
first Down-regulated daily dose | 1000mg BID |
Second Down-regulated daily dose | 800mg BID |
MET gene status assessment
For mutation, amplification and overexpression of the MET gene in NSCLC patients, corresponding detection methods comprise a direct sequencing method, real-time fluorescent quantitative PCR (RTFQ-PCR), FISH and IHC, and people who benefit from the application of the c-MET inhibitor are necessarily screened by analyzing the MET gene and the c-MET protein.
The direct sequencing method has high accuracy in detecting the MET gene mutation, and other potential exon mutation sites can be detected without determining the specific position of the MET gene mutation site; RTFQ-PCR and FISH can be used for MET gene amplification detection, the detection speed of the RTFQ-PCR is higher, but the quality requirement on genome DNA fragments is higher, and the quality of the genome DNA fragments obtained by the existing extraction method is poorer, so that the FISH application is wider compared with the RTFQ-PCR and the FISH. The FISH method can determine the MET gene copy number (MET gene copies number, MET GCN) by detecting the ratio of fluorescent probes of MET and CEP7 (as a control), and the evaluation standard can be based on two aspects: (1) the fluorescent probe ratio of MET/CEP 7; (2) the copy number of the gene of each cell and the proportion of the positive cells in the total cells. IHC can be used for detecting the overexpression condition of the c-MET protein.
Examples MET gene abnormalities in clinical trials include exon 14 skipping mutations of the MET gene, MET gene amplification (including 2: average gene copy number. Gtoreq.5 and/or MET/CEP-7 copy number. Gtoreq.2).
Preliminary results show efficacy in NSCLC patients where the efficacy of MET gene abnormalities can be assessed.
Example 5-1
Male, age 81, clinical diagnosis: in stage IV of lung adenocarcinoma, mediastinal lymph node metastasis and diplocardia metastasis, no chemotherapy history exists, and gene detection indicates exon 14 skipping mutation of MET gene.
600mg of compound I citrate capsules prepared in example 2 are initially taken 2 times daily and orally, continuously daily, approximately the same time each day, with two recommended intervals of 10-12 hours, either on an empty stomach or with meals, for 1 treatment cycle every 28 days.
CT scans before compound I citrate capsules showed that the sum of measurable target lesion diameters was 55mm, CT scans were performed periodically after dosing, and after one cycle of treatment, the sum of target lesion diameters decreased to 37.5mm, and the efficacy was evaluated as PR, which decreased by more than 30%. After 3 and 5 cycles of treatment, the sum of the diameters of the target lesions is reduced to 31.2mm and 31.1mm, and the curative effect is evaluated as PR. During treatment, overall tolerability was good.
Example 5-2
Male, age 79, puncture, pathological diagnosis suggestion: non-small cell lung cancer, adenocarcinoma. And (3) clinical diagnosis: primary right lung adenocarcinoma, lymph node metastasis, no distant metastasis. Gene detection suggests MET gene amplification with no history of chemotherapy.
Subsequently, 600mg of compound I citrate capsules prepared in example 2 were administered orally 2 times daily for 1 treatment cycle every 28 days with a continuous daily dose approximately the same time in the morning and evening, with two recommended intervals of 10-12 hours, and with an empty stomach or with meals.
CT scans showed a measurable sum of target lesion diameters of 27.7mm before compound I citrate capsules were administered, and CT scans were performed periodically after dosing, with the sum of target lesion diameters decreasing to 17.7mm after one cycle of treatment, with a reduction in efficacy rating of PR of over 30%. After 3 and 5 cycles of treatment, the sum of the diameters of the target lesions decreased to 15.4mm and 14.4mm, and the efficacy was evaluated as PR. During treatment, overall tolerability was good.
Examples 5 to 3
Male, 72 years old, puncture, pathological diagnosis prompt: non-small cell lung cancer, poorly differentiated adenocarcinoma. And (3) clinical diagnosis: stage iv lung adenocarcinoma, mediastinal lymph node metastasis. Gene detection suggests that the MET gene 14 exon skipping mutation has no chemotherapy history.
Subsequently, 600mg of compound I citrate capsules prepared in example 2 were administered orally 2 times daily for 1 treatment cycle every 28 days with a continuous daily dose approximately the same time in the morning and evening, with two recommended intervals of 10-12 hours, and with an empty stomach or with meals.
CT scans showed that the sum of measurable target lesion diameters was 111.2mm before administration of citrate capsules of compound I, and CT scans were performed periodically after administration, and after one cycle of treatment, the sum of target lesion diameters decreased to 71.2mm, and the efficacy was evaluated as PR, which decreased by more than 30%. After 3 cycles of treatment, the target lesion diameter dropped to 70.8mm and the efficacy was evaluated as PR, with the patient still on treatment. During treatment, overall tolerability was good.
Examples 5 to 4
Male, age 85, clinical diagnosis: non-small cell lung cancer, left lung malignant tumor pleural metastasis (adenocarcinoma, stage IV, KPS score 90 points), gene detection suggests MET gene exon 14 skipping mutation.
Prior to enrollment, patients received 125mg po qd of icotinib (1 month of treatment, no efficacy assessment); and bevacizumab thoracic cavity infusion therapy (no efficacy assessment).
Subsequently, 600mg of a citrate capsule of compound I prepared in example 2 was administered orally 2 times daily for 2 consecutive daily administrations in the morning and evening, with two intervals of 10-12 hours recommended, orally on an empty stomach or with meals, for 1 treatment cycle every 28 days.
CT scans before administration of citrate capsules of compound I showed that the sum of measurable target lesion diameters was 34.7mm, CT scans were performed periodically after administration, and after one cycle of treatment, the sum of target lesion diameters decreased to 21.2mm, and the efficacy was evaluated as PR, which decreased by more than 30%. After 3 and 5 cycles of treatment, the sum of the target lesion diameters dropped to 18mm and the efficacy was evaluated as PR, with the patient still on treatment. During treatment, overall tolerability was good.
Claims (13)
- the use according to claim 1 or 5, the method according to claim 2, the pharmaceutical composition according to claim 3 or the kit according to claim 4, wherein the disease with abnormal MET gene is non-small cell lung cancer with abnormal MET gene or gastric cancer with abnormal MET gene.
- The use according to claim 1, 5 or 6, the method according to claim 2 or 6, the pharmaceutical composition according to claim 3 or 6 or the kit according to claim 4 or 6, wherein the MET gene abnormality is selected from MET gene amplification, MET gene rearrangement, MET gene mutation and/or c-MET overexpression.
- The use according to any one of claims 1 and 5-7, the method of claim 2,6 or 7, the pharmaceutical composition of claim 3, 6 or 7 or the kit of claim 4, 6 or 7, wherein the disease with abnormal MET gene is a disease with abnormal MET gene in which treatment with at least one chemotherapeutic drug and/or targeted drug fails.
- The use according to any one of claims 1 and 5 to 8, the method according to any one of claims 2 and 6 to 8, the pharmaceutical composition according to any one of claims 3 and 6 to 8 or the kit according to any one of claims 4 and 6 to 8, wherein the disease with abnormal MET gene is non-small cell lung cancer with abnormal MET gene that fails at least one chemotherapeutic drug and/or targeted drug therapy or non-small cell lung cancer that progresses or recurs after first receiving at least one chemotherapeutic drug and/or targeted drug therapy, or gastric cancer with abnormal MET gene that fails at least one chemotherapeutic drug and/or targeted drug therapy or gastric cancer with abnormal MET gene that is at least one chemotherapeutic drug and/or targeted drug resistant.
- The use according to any one of claims 1 and 5-9, the method of any one of claims 2 and 6-9, the pharmaceutical composition of any one of claims 3 and 6-9, or the kit of any one of claims 4 and 6-9, wherein the pharmaceutically acceptable salt of compound I is a salt of compound I with any of the following acids: sulfuric acid, carbonic acid, nitric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, metaphosphoric acid, trifluoroacetic acid, lactic acid, mandelic acid, glycolic acid, p-toluenesulfonic acid, o-toluenesulfonic acid, citric acid, methanesulfonic acid, formic acid, acetic acid, benzoic acid, phenylacetic acid, malonic acid, cinnamic acid, malic acid, maleic acid, tartaric acid, oxalic acid, fumaric acid, acrylic acid, crotonic acid, oleic acid, and linoleic acid.
- The use according to any one of claims 1 and 5-10, the method of any one of claims 2 and 6-10, the pharmaceutical composition of any one of claims 3 and 6-10, or the kit of any one of claims 4 and 6-10, wherein the pharmaceutically acceptable salt of compound I is citrate.
- The use according to any one of claims 1 and 5-11, the method of any one of claims 2 and 6-11, the pharmaceutical composition of any one of claims 3 and 6-11, or the kit of any one of claims 4 and 6-11, wherein the compound I or the pharmaceutically acceptable salt thereof is administered in a daily dose selected from the group consisting of 100 mg to 2000 mg, 150 mg to 1950 mg, 200mg to 1900 mg, 300 mg to 1800 mg, 450 mg to 1750 mg, 500 mg to 1650 mg, 750 mg to 1500 mg, 900 mg to 1350 mg, 1050 mg to 1250 mg, 200mg, 400 mg, 600mg, 800mg, 1000mg, 1200mg, or 1600 mg.
- The use according to any one of claims 1 and 5 to 12, the method according to any one of claims 2 and 6 to 12, the pharmaceutical composition according to any one of claims 3 and 6 to 12 or the kit according to any one of claims 4 and 6 to 12, wherein compound I or the pharmaceutically acceptable salt thereof is administered on a daily basis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020103661177 | 2020-04-30 | ||
CN202010366117 | 2020-04-30 | ||
PCT/CN2021/091584 WO2021219137A1 (en) | 2020-04-30 | 2021-04-30 | Aminopyridine derivative for treating diseases caused by met genetic abnormalities |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115484955A true CN115484955A (en) | 2022-12-16 |
Family
ID=78373344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180030830.7A Pending CN115484955A (en) | 2020-04-30 | 2021-04-30 | Aminopyridine derivatives for the treatment of disorders of MET gene abnormality |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115484955A (en) |
WO (1) | WO2021219137A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1786777A1 (en) * | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
WO2014117718A1 (en) * | 2013-02-02 | 2014-08-07 | 正大天晴药业集团股份有限公司 | Substituted 2-aminopyridine protein kinase inhibitor |
CN104650049B (en) * | 2013-08-28 | 2018-06-08 | 广东东阳光药业有限公司 | Substituted pyridine compounds and its application method and purposes |
WO2015034729A1 (en) * | 2013-09-05 | 2015-03-12 | Calitor Sciences, Llc | Substituted pyridine compounds and methods of use |
US9981946B2 (en) * | 2014-07-31 | 2018-05-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridine-substituted 2-aminopyridine protein kinase inhibitors |
JP6513294B2 (en) * | 2015-07-30 | 2019-05-15 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystals of pyridine-substituted 2-aminopyridines protein kinase inhibitors |
CN107721894A (en) * | 2016-08-12 | 2018-02-23 | 正大天晴药业集团股份有限公司 | A kind of preparation method of the intermediate of 6 arylamino pyridine ketone formamide mek inhibitor compound |
CN108264500B (en) * | 2016-12-31 | 2020-04-21 | 正大天晴药业集团股份有限公司 | Substituted 2-aminopyridines and preparation method thereof |
CN114173785A (en) * | 2019-08-01 | 2022-03-11 | 正大天晴药业集团股份有限公司 | Aminopyridine derivatives for the treatment of non-small cell lung cancer |
-
2021
- 2021-04-30 WO PCT/CN2021/091584 patent/WO2021219137A1/en active Application Filing
- 2021-04-30 CN CN202180030830.7A patent/CN115484955A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021219137A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019314624B2 (en) | Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
RU2761953C2 (en) | Treatment of stomach cancer using combination types of therapy containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
EP3672595B1 (en) | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | |
EP3231797B1 (en) | Quinoline derivative against non-small cell lung cancer | |
US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
TWI798199B (en) | Cancer treatment | |
CN110650741A (en) | Quinoline derivatives for the treatment of colorectal cancer | |
CN111643503A (en) | Quinoline derivatives for the treatment of non-small cell lung cancer | |
TW202019421A (en) | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof | |
JP2023022190A (en) | cancer treatment | |
AU2018278336A1 (en) | Biomarkers and patient selection strategies | |
EP4326256A1 (en) | Treatment of cancer with a raf inhibitor | |
CN115006397A (en) | Pharmaceutical application for preventing or treating tumor diseases | |
CN114173785A (en) | Aminopyridine derivatives for the treatment of non-small cell lung cancer | |
CN110840892A (en) | Use of a tyrosine kinase inhibitor in combination with a CDK4/6 inhibitor for the preparation of a medicament for the prevention or treatment of a neoplastic disease | |
CN112638385B (en) | Quinoline derivatives for the treatment of brain tumors | |
WO2018099423A1 (en) | Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer | |
KR20190099253A (en) | Combination of Protein Kinase Inhibitors and Additional Chemotherapy Agents | |
US11890292B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
CN115484955A (en) | Aminopyridine derivatives for the treatment of disorders of MET gene abnormality | |
WO2022017508A1 (en) | Combination therapy of parp inhibitors | |
CN117797151A (en) | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer | |
CN112533600B (en) | Quinoline derivatives for the treatment of small cell lung cancer | |
JP2014034531A (en) | Combination of hsp90 inhibitor and gemcitabine | |
WO2024088193A1 (en) | Combination of aurora a and parp inhibitors for treatment of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |